---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-003781"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:48:12.581499+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Foghorn announces Lilly selects FHD-909 for clinical development; IND planned for Q2 2024

## Summary
- Lilly selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development.
- Lilly plans to file an IND for FHD-909 in Q2 2024 for BRG1 mutated NSCLC.
- FHD-909 targets BRG1 mutant non-small cell lung cancer, exploiting BRM dependency.
- Collaboration with Lilly announced Dec 2021 includes US 50/50 co-development and co-commercialization.
- Foghorn and Lilly plan to present preclinical data at upcoming scientific conferences.

## SEC filing metadata
- accession: 0001628280-24-003781
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828024003781/0001628280-24-003781-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828024003781/fhtx-20240208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-003781
- JSON: https://secwatch.observer/filing/0001628280-24-003781.json
- Plain text: https://secwatch.observer/filing/0001628280-24-003781.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.